BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ratziu V, Giral P, Charlotte F, Bruckert E, Thibault V, Theodorou I, Khalil L, Turpin G, Opolon P, Poynard T. Liver fibrosis in overweight patients. Gastroenterology. 2000;118:1117-1123. [PMID: 10833486 DOI: 10.1016/s0016-5085(00)70364-7] [Cited by in Crossref: 628] [Cited by in F6Publishing: 195] [Article Influence: 28.5] [Reference Citation Analysis]
Number Citing Articles
1 Alazmi WM, Regev A, Molina EG, Schiff ER. Predictors of cirrhosis in Hispanic patients with nonalcoholic steatohepatitis. Dig Dis Sci 2006;51:1725-9. [PMID: 16958001 DOI: 10.1007/s10620-005-9065-1] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
2 Marcuccilli M, Chonchol M. NAFLD and Chronic Kidney Disease. Int J Mol Sci. 2016;17:562. [PMID: 27089331 DOI: 10.3390/ijms17040562] [Cited by in Crossref: 64] [Cited by in F6Publishing: 60] [Article Influence: 10.7] [Reference Citation Analysis]
3 Siebler J, Schuchmann M, Strand S, Lehr HA, Neurath MF, Galle PR. Enhanced sensitivity to CD95-induced apoptosis in ob/ob mice. Dig Dis Sci. 2007;52:2396-2402. [PMID: 17415659 DOI: 10.1007/s10620-006-9148-7] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 0.7] [Reference Citation Analysis]
4 Riley TR, Kahn A. Risk factors and ultrasound can predict chronic hepatitis caused by nonalcoholic fatty liver disease. Dig Dis Sci. 2006;51:41-44. [PMID: 16416209 DOI: 10.1007/s10620-006-3082-6] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
5 Rasool A, Dar W, Latief M, Dar I, Sofi N, Khan MA. Nonalcoholic fatty liver disease as an independent risk factor for carotid atherosclerosis. Brain Circ 2017;3:35-40. [PMID: 30276302 DOI: 10.4103/bc.bc_28_16] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
6 Mohamed AA, El-Demery A, Al-Hussain E, Mousa S, Halim AA, Mostafa SM, Abdelghany RS, Mahmoud SM, Elkady MA, Raafat K, Hassnine AA, Omran MM. NAFLD mark: an accurate model based on microRNA-34 for diagnosis of non-alcoholic fatty liver disease patients. J Genet Eng Biotechnol 2021;19:157. [PMID: 34661762 DOI: 10.1186/s43141-021-00257-5] [Reference Citation Analysis]
7 Pulzi FB, Cisternas R, Melo MR, Ribeiro CM, Malheiros CA, Salles JE. New clinical score to diagnose nonalcoholic steatohepatitis in obese patients. Diabetol Metab Syndr. 2011;3:3. [PMID: 21345221 DOI: 10.1186/1758-5996-3-3] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 2.6] [Reference Citation Analysis]
8 Kamada Y, Takehara T, Hayashi N. Adipocytokines and liver disease. J Gastroenterol. 2008;43:811-822. [PMID: 19012034 DOI: 10.1007/s00535-008-2213-6] [Cited by in Crossref: 103] [Cited by in F6Publishing: 96] [Article Influence: 7.4] [Reference Citation Analysis]
9 Syn WK, Nightingale P, Bateman JM. Nonalcoholic fatty liver disease in a district general hospital: clinical presentation and risk factors. Hepatol Int 2008;2:190-5. [PMID: 19669303 DOI: 10.1007/s12072-008-9044-7] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
10 Chaim FDM, Pascoal LB, Chaim FHM, Palma BB, Damázio TA, da Costa LBE, Carvalho R, Cazzo E, Gestic MA, Utrini MP, Milanski M, Chaim EA, Leal RF. Histological grading evaluation of non-alcoholic fatty liver disease after bariatric surgery: a retrospective and longitudinal observational cohort study. Sci Rep 2020;10:8496. [PMID: 32444690 DOI: 10.1038/s41598-020-65556-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
11 Cantero I, Abete I, Monreal JI, Martinez JA, Zulet MA. Fruit Fiber Consumption Specifically Improves Liver Health Status in Obese Subjects under Energy Restriction. Nutrients 2017;9:E667. [PMID: 28657604 DOI: 10.3390/nu9070667] [Cited by in Crossref: 36] [Cited by in F6Publishing: 31] [Article Influence: 7.2] [Reference Citation Analysis]
12 Singh SP, Barik RK. NonInvasive Biomarkers in Nonalcoholic Fatty Liver Disease: Are We There Yet? J Clin Exp Hepatol 2020;10:88-98. [PMID: 32025168 DOI: 10.1016/j.jceh.2019.09.006] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
13 Kamada Y, Miyoshi E. Mac-2 Binding Protein is a Useful Liver Fibrosis Biomarker for NAFLD/NASH. Trends in Glycoscience and Glycotechnology 2017;29:J61-8. [DOI: 10.4052/tigg.1714.1j] [Reference Citation Analysis]
14 Cauchy F, Belghiti J. A clinical perspective of the link between metabolic syndrome and hepatocellular carcinoma. J Hepatocell Carcinoma 2015;2:19-27. [PMID: 27508191 DOI: 10.2147/JHC.S44521] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
15 Gill HK, Wu GY. Non-alcoholic fatty liver disease and the metabolic syndrome: Effects of weight loss and a review of popular diets. Are low carbohydrate diets the answer? World J Gastroenterol 2006; 12(3): 345-353 [PMID: 16489632 DOI: 10.3748/wjg.v12.i3.345] [Cited by in CrossRef: 31] [Cited by in F6Publishing: 27] [Article Influence: 1.9] [Reference Citation Analysis]
16 Alkhouri N, McCullough AJ. Noninvasive Diagnosis of NASH and Liver Fibrosis Within the Spectrum of NAFLD. Gastroenterol Hepatol (N Y). 2012;8:661-668. [PMID: 24683373 DOI: 10.1016/s0016-5085(10)62097-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
17 Saponaro C, Gaggini M, Gastaldelli A. Nonalcoholic fatty liver disease and type 2 diabetes: common pathophysiologic mechanisms. Curr Diab Rep. 2015;15:607. [PMID: 25894944 DOI: 10.1007/s11892-015-0607-4] [Cited by in Crossref: 61] [Cited by in F6Publishing: 61] [Article Influence: 8.7] [Reference Citation Analysis]
18 Poynard T, Ratziu V, Charlotte F, Messous D, Munteanu M, Imbert-Bismut F, Massard J, Bonyhay L, Tahiri M, Thabut D, Cadranel JF, Le Bail B, de Ledinghen V; LIDO Study Group; CYTOL study group. Diagnostic value of biochemical markers (NashTest) for the prediction of non alcoholo steato hepatitis in patients with non-alcoholic fatty liver disease. BMC Gastroenterol. 2006;6:34. [PMID: 17096854 DOI: 10.1186/1471-230x-6-34] [Cited by in Crossref: 186] [Cited by in F6Publishing: 72] [Article Influence: 11.6] [Reference Citation Analysis]
19 Eguchi Y, Hyogo H, Ono M, Mizuta T, Ono N, Fujimoto K, Chayama K, Saibara T;  JSG-NAFLD. Prevalence and associated metabolic factors of nonalcoholic fatty liver disease in the general population from 2009 to 2010 in Japan: a multicenter large retrospective study. J Gastroenterol. 2012;47:586-595. [PMID: 22328022 DOI: 10.1007/s00535-012-0533-z] [Cited by in Crossref: 268] [Cited by in F6Publishing: 232] [Article Influence: 26.8] [Reference Citation Analysis]
20 Becker PP, Rau M, Schmitt J, Malsch C, Hammer C, Bantel H, Müllhaupt B, Geier A. Performance of Serum microRNAs -122, -192 and -21 as Biomarkers in Patients with Non-Alcoholic Steatohepatitis. PLoS One. 2015;10:e0142661. [PMID: 26565986 DOI: 10.1371/journal.pone.0142661] [Cited by in Crossref: 74] [Cited by in F6Publishing: 75] [Article Influence: 10.6] [Reference Citation Analysis]
21 Poynard T, Lassailly G, Diaz E, Clement K, Caïazzo R, Tordjman J, Munteanu M, Perazzo H, Demol B, Callafe R. Performance of biomarkers FibroTest, ActiTest, SteatoTest, and NashTest in patients with severe obesity: meta analysis of individual patient data. PLoS One. 2012;7:e30325. [PMID: 22431959 DOI: 10.1371/journal.pone.0030325] [Cited by in Crossref: 83] [Cited by in F6Publishing: 76] [Article Influence: 8.3] [Reference Citation Analysis]
22 Hsu CS, Lang HC, Huang KY, Chao YC, Chen CL. Risks of hepatocellular carcinoma and cirrhosis-associated complications in patients with rheumatoid arthritis: a 10-year population-based cohort study in Taiwan. Hepatol Int 2018;12:531-43. [PMID: 30426396 DOI: 10.1007/s12072-018-9905-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
23 Boland ML, Oró D, Tølbøl KS, Thrane ST, Nielsen JC, Cohen TS, Tabor DE, Fernandes F, Tovchigrechko A, Veidal SS, Warrener P, Sellman BR, Jelsing J, Feigh M, Vrang N, Trevaskis JL, Hansen HH. Towards a standard diet-induced and biopsy-confirmed mouse model of non-alcoholic steatohepatitis: Impact of dietary fat source. World J Gastroenterol 2019; 25(33): 4904-4920 [PMID: 31543682 DOI: 10.3748/wjg.v25.i33.4904] [Cited by in CrossRef: 24] [Cited by in F6Publishing: 21] [Article Influence: 8.0] [Reference Citation Analysis]
24 Liu CM, Tung TH, Liu JH, Chen VTK, Lin CH, Hsu CT, Chou P. A community-based epidemiological study of elevated serum alanine aminotransferase levels in Kinmen, Taiwan. World J Gastroenterol 2005; 11(11): 1616-1622 [PMID: 15786537 DOI: 10.3748/wjg.v11.i11.1616] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 14] [Article Influence: 1.0] [Reference Citation Analysis]
25 Mohamed MS, Youssef TM, Abdullah EE, Ahmed AE. Correlation between adiponectin level and the degree of fibrosis in patients with non-alcoholic fatty liver disease. Egypt Liver Journal 2021;11. [DOI: 10.1186/s43066-021-00134-3] [Reference Citation Analysis]
26 Ferolla SM, Couto CA, Costa-Silva L, Armiliato GN, Pereira CA, Martins FS, Ferrari Mde L, Vilela EG, Torres HO, Cunha AS, Ferrari TC. Beneficial Effect of Synbiotic Supplementation on Hepatic Steatosis and Anthropometric Parameters, But Not on Gut Permeability in a Population with Nonalcoholic Steatohepatitis. Nutrients 2016;8:E397. [PMID: 27367724 DOI: 10.3390/nu8070397] [Cited by in Crossref: 49] [Cited by in F6Publishing: 42] [Article Influence: 8.2] [Reference Citation Analysis]
27 Ekstedt M, Nasr P, Kechagias S. Natural History of NAFLD/NASH. Curr Hepatol Rep. 2017;16:391-397. [PMID: 29984130 DOI: 10.1007/s11901-017-0378-2] [Cited by in Crossref: 51] [Cited by in F6Publishing: 53] [Article Influence: 10.2] [Reference Citation Analysis]
28 Castera L, Vilgrain V, Angulo P. Noninvasive evaluation of NAFLD. Nat Rev Gastroenterol Hepatol 2013;10:666-75. [PMID: 24061203 DOI: 10.1038/nrgastro.2013.175] [Cited by in Crossref: 168] [Cited by in F6Publishing: 146] [Article Influence: 18.7] [Reference Citation Analysis]
29 Onal IK. Endothelial dysfunction in patients with non-alcoholic steatohepatitis. Ups J Med Sci 2014;119:290-1. [PMID: 24397312 DOI: 10.3109/03009734.2013.872736] [Reference Citation Analysis]
30 Uslusoy HS, Nak SG, Gülten M. Noninvasive predictors for liver fibrosis in patients with nonalcoholic steatohepatitis. World J Hepatol 2011; 3(8): 219-227 [PMID: 21954411 DOI: 10.4254/wjh.v3.i8.219] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
31 Friedman SL, Neuschwander-Tetri BA, Rinella M, Sanyal AJ. Mechanisms of NAFLD development and therapeutic strategies. Nat Med. 2018;24:908-922. [PMID: 29967350 DOI: 10.1038/s41591-018-0104-9] [Cited by in Crossref: 777] [Cited by in F6Publishing: 742] [Article Influence: 194.3] [Reference Citation Analysis]
32 Bugianesi E, Vanni E, Marchesini G. NASH and the risk of cirrhosis and hepatocellular carcinoma in type 2 diabetes. Curr Diab Rep. 2007;7:175-180. [PMID: 17547834 DOI: 10.1007/s11892-007-0029-z] [Cited by in Crossref: 37] [Cited by in F6Publishing: 35] [Article Influence: 2.5] [Reference Citation Analysis]
33 Sîrbu O, Floria M, Dăscălița P, Şorodoc V, Şorodoc L. Non-alcoholic fatty liver disease-From the cardiologist perspective. Anatol J Cardiol 2016;16:534-41. [PMID: 27389154 DOI: 10.14744/AnatolJCardiol.2016.7049] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
34 Kroh M, Liu R, Chand B. Laparoscopic bariatric surgery: what else are we uncovering? Liver pathology and preoperative indicators of advanced liver disease in morbidly obese patients. Surg Endosc 2007;21:1957-60. [PMID: 17479322 DOI: 10.1007/s00464-007-9351-4] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.0] [Reference Citation Analysis]
35 Sumida Y, Yoneda M, Hyogo H, Itoh Y, Ono M, Fujii H, Eguchi Y, Suzuki Y, Aoki N, Kanemasa K, Fujita K, Chayama K, Saibara T, Kawada N, Fujimoto K, Kohgo Y, Yoshikawa T, Okanoue T;  Japan Study Group of Nonalcoholic Fatty Liver Disease (JSG-NAFLD). Validation of the FIB4 index in a Japanese nonalcoholic fatty liver disease population. BMC Gastroenterol. 2012;12:2. [PMID: 22221544 DOI: 10.1186/1471-230x-12-2] [Cited by in Crossref: 181] [Cited by in F6Publishing: 104] [Article Influence: 18.1] [Reference Citation Analysis]
36 Liu TW, Huang CF, Yeh ML, Tsai PC, Jang TY, Huang JF, Dai CY, Chuang WL, Yu ML. Less liver fibrosis marker increment in overweight chronic hepatitis B patients observed by age-adjusted Fibrosis-4 Index. BMJ Open Gastroenterol 2020;7:e000543. [PMID: 33323472 DOI: 10.1136/bmjgast-2020-000543] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
37 Tincopa MA. Diagnostic and interventional circulating biomarkers in nonalcoholic steatohepatitis. Endocrinol Diabetes Metab 2020;3:e00177. [PMID: 33102798 DOI: 10.1002/edm2.177] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
38 Kallwitz ER, Kumar M, Aggarwal R, Berger R, Layden-Almer J, Gupta N, Cotler SJ. Ethnicity and nonalcoholic fatty liver disease in an obesity clinic: the impact of triglycerides. Dig Dis Sci. 2008;53:1358-1363. [PMID: 18347982 DOI: 10.1007/s10620-008-0234-x] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 2.1] [Reference Citation Analysis]
39 Lückhoff HK, Kruger FC, Kotze MJ. Composite prognostic models across the non-alcoholic fatty liver disease spectrum: Clinical application in developing countries. World J Hepatol 2015; 7(9): 1192-1208 [PMID: 26019735 DOI: 10.4254/wjh.v7.i9.1192] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
40 Perseghin G. Lipids in the wrong place: visceral fat and nonalcoholic steatohepatitis. Diabetes Care. 2011;34 Suppl 2:S367-S370. [PMID: 21525484 DOI: 10.2337/dc11-s249] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 2.3] [Reference Citation Analysis]
41 Osaki A, Kubota T, Suda T, Igarashi M, Nagasaki K, Tsuchiya A, Yano M, Tamura Y, Takamura M, Kawai H, Yamagiwa S, Kikuchi T, Nomoto M, Aoyagi Y. Shear wave velocity is a useful marker for managing nonalcoholic steatohepatitis. World J Gastroenterol 2010; 16(23): 2918-2925 [PMID: 20556839 DOI: 10.3748/wjg.v16.i23.2918] [Cited by in CrossRef: 58] [Cited by in F6Publishing: 53] [Article Influence: 4.8] [Reference Citation Analysis]
42 Daryani NE, Daryani NE, Alavian SM, Zare A, Fereshtehnejad SM, Keramati MR, Pashaei MR, Habibollahi P. Non-alcoholic steatohepatitis and influence of age and gender on histopathologic findings. World J Gastroenterol 2010; 16(33): 4169-4175 [PMID: 20806434 DOI: 10.3748/wjg.v16.i33.4169] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
43 Qureshi K, Abrams GA. Metabolic liver disease of obesity and role of adipose tissue in the pathogenesis of nonalcoholic fatty liver disease. World J Gastroenterol 2007; 13(26): 3540-3553 [PMID: 17659704 DOI: 10.3748/wjg.v13.i26.3540] [Cited by in CrossRef: 160] [Cited by in F6Publishing: 148] [Article Influence: 10.7] [Reference Citation Analysis]
44 Brunt EM, Kleiner DE, Wilson LA, Unalp A, Behling CE, Lavine JE, Neuschwander-Tetri BA; NASH Clinical Research NetworkA list of members of the Nonalcoholic Steatohepatitis Clinical Research Network can be found in the Appendix. Portal chronic inflammation in nonalcoholic fatty liver disease (NAFLD): a histologic marker of advanced NAFLD-Clinicopathologic correlations from the nonalcoholic steatohepatitis clinical research network. Hepatology 2009;49:809-20. [PMID: 19142989 DOI: 10.1002/hep.22724] [Cited by in Crossref: 243] [Cited by in F6Publishing: 222] [Article Influence: 18.7] [Reference Citation Analysis]
45 Khanam A, Saleeb PG, Kottilil S. Pathophysiology and Treatment Options for Hepatic Fibrosis: Can It Be Completely Cured? Cells 2021;10:1097. [PMID: 34064375 DOI: 10.3390/cells10051097] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
46 Basaranoglu M, Basaranoglu G, Sentürk H. From fatty liver to fibrosis: A tale of “second hit”. World J Gastroenterol 2013; 19(8): 1158-1165 [PMID: 23483818 DOI: 10.3748/wjg.v19.i8.1158] [Cited by in CrossRef: 100] [Cited by in F6Publishing: 96] [Article Influence: 11.1] [Reference Citation Analysis]
47 Sentinelli F, Romeo S, Maglio C, Incani M, Burza MA, Scano F, Coccia F, Cossu E, Leonetti F, Baroni MG. Lack of effect of apolipoprotein C3 polymorphisms on indices of liver steatosis, lipid profile and insulin resistance in obese Southern Europeans. Lipids Health Dis. 2011;10:93. [PMID: 21663607 DOI: 10.1186/1476-511x-10-93] [Cited by in Crossref: 28] [Cited by in F6Publishing: 15] [Article Influence: 2.5] [Reference Citation Analysis]
48 Rodríguez-Suárez E, Duce AM, Caballería J, Martínez Arrieta F, Fernández E, Gómara C, Alkorta N, Ariz U, Martínez-Chantar ML, Lu SC. Non-alcoholic fatty liver disease proteomics. Proteomics Clin Appl. 2010;4:362-371. [PMID: 21137056 DOI: 10.1002/prca.200900119] [Cited by in Crossref: 35] [Cited by in F6Publishing: 35] [Article Influence: 2.9] [Reference Citation Analysis]
49 Neuschwander-Tetri BA, Clark JM, Bass NM, Van Natta ML, Unalp-Arida A, Tonascia J, Zein CO, Brunt EM, Kleiner DE, McCullough AJ, Sanyal AJ, Diehl AM, Lavine JE, Chalasani N, Kowdley KV; NASH Clinical Research Network. Clinical, laboratory and histological associations in adults with nonalcoholic fatty liver disease. Hepatology 2010;52:913-24. [PMID: 20648476 DOI: 10.1002/hep.23784] [Cited by in Crossref: 290] [Cited by in F6Publishing: 276] [Article Influence: 24.2] [Reference Citation Analysis]
50 Yan K, Deng X, Zhai X, Zhou M, Jia X, Luo L, Niu M, Zhu H, Qiang H, Zhou Y. p38 mitogen-activated protein kinase and liver X receptor-α mediate the leptin effect on sterol regulatory element binding protein-1c expression in hepatic stellate cells. Mol Med 2012;18:10-8. [PMID: 21979752 DOI: 10.2119/molmed.2011.00243] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 3.1] [Reference Citation Analysis]
51 Cichoż-Lach H, Celiński K, Prozorow-Król B, Swatek J, Słomka M, Lach T. The BARD score and the NAFLD fibrosis score in the assessment of advanced liver fibrosis in nonalcoholic fatty liver disease. Med Sci Monit 2012;18:CR735-40. [PMID: 23197236 DOI: 10.12659/msm.883601] [Cited by in Crossref: 24] [Cited by in F6Publishing: 15] [Article Influence: 2.7] [Reference Citation Analysis]
52 Kaswala DH, Lai M, Afdhal NH. Fibrosis Assessment in Nonalcoholic Fatty Liver Disease (NAFLD) in 2016. Dig Dis Sci. 2016;61:1356-1364. [PMID: 27017224 DOI: 10.1007/s10620-016-4079-4] [Cited by in Crossref: 70] [Cited by in F6Publishing: 59] [Article Influence: 11.7] [Reference Citation Analysis]
53 Mills SJ, Harrison SA. Comparison of the natural history of alcoholic and nonalcoholic fatty liver disease. Curr Gastroenterol Rep. 2005;7:32-36. [PMID: 15701296 DOI: 10.1007/s11894-005-0063-4] [Cited by in Crossref: 36] [Cited by in F6Publishing: 36] [Article Influence: 2.6] [Reference Citation Analysis]
54 Arora A, Sharma P. Non-invasive Diagnosis of Fibrosis in Non-alcoholic Fatty Liver Disease. J Clin Exp Hepatol. 2012;2:145-155. [PMID: 25755423 DOI: 10.1016/s0973-6883(12)60103-0] [Cited by in Crossref: 25] [Cited by in F6Publishing: 13] [Article Influence: 2.5] [Reference Citation Analysis]
55 Enomoto H, Bando Y, Nakamura H, Nishiguchi S, Koga M. Liver fibrosis markers of nonalcoholic steatohepatitis. World J Gastroenterol 2015; 21(24): 7427-7435 [PMID: 26139988 DOI: 10.3748/wjg.v21.i24.7427] [Cited by in CrossRef: 27] [Cited by in F6Publishing: 22] [Article Influence: 3.9] [Reference Citation Analysis]
56 Kamble R, Sodhi KS, Thapa BR, Saxena AK, Bhatia A, Dayal D, Khandelwal N. Liver acoustic radiation force impulse (ARFI) in childhood obesity: comparison and correlation with biochemical markers. J Ultrasound 2017;20:33-42. [PMID: 28298942 DOI: 10.1007/s40477-016-0229-y] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
57 Chen YL, Li H, Li S, Xu Z, Tian S, Wu J, Liang XY, Li X, Liu ZL, Xiao J, Wei JY, Ma CY, Wu KN, Ran L, Kong LQ. Prevalence of and risk factors for metabolic associated fatty liver disease in an urban population in China: a cross-sectional comparative study. BMC Gastroenterol 2021;21:212. [PMID: 33971822 DOI: 10.1186/s12876-021-01782-w] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
58 Duvnjak M, Lerotić I, Baršić N, Tomašić V, Jukić LV, Velagić V. Pathogenesis and management issues for non-alcoholic fatty liver disease. World J Gastroenterol 2007; 13(34): 4539-4550 [PMID: 17729403 DOI: 10.3748/wjg.v13.i34.4539] [Cited by in CrossRef: 157] [Cited by in F6Publishing: 142] [Article Influence: 10.5] [Reference Citation Analysis]
59 Ghoghaei M, Taghdiri F, Khajeh E, Azmoudeh Ardalan F, Sedaghat M, Hosseini Shirvani S, Zarei S, Toolabi K. Parathyroid Hormone Levels May Predict Nonalcoholic Steatohepatitis in Morbidly Obese Patients. Hepat Mon 2015;15:e29697. [PMID: 26300934 DOI: 10.5812/hepatmon.29697v2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
60 Lau JK, Zhang X, Yu J. Animal models of non-alcoholic fatty liver disease: current perspectives and recent advances. J Pathol. 2017;241:36-44. [PMID: 27757953 DOI: 10.1002/path.4829] [Cited by in Crossref: 162] [Cited by in F6Publishing: 153] [Article Influence: 27.0] [Reference Citation Analysis]
61 Cantero I, Abete I, Del Bas JM, Caimari A, Arola L, Zulet MA, Martinez JA. Changes in lysophospholipids and liver status after weight loss: the RESMENA study. Nutr Metab (Lond) 2018;15:51. [PMID: 30026784 DOI: 10.1186/s12986-018-0288-5] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
62 Cho Y, Tokuhara D, Morikawa H, Kuwae Y, Hayashi E, Hirose M, Hamazaki T, Tanaka A, Kawamura T, Kawada N. Transient Elastography-Based Liver Profiles in a Hospital-Based Pediatric Population in Japan. PLoS One. 2015;10:e0137239. [PMID: 26398109 DOI: 10.1371/journal.pone.0137239] [Cited by in Crossref: 36] [Cited by in F6Publishing: 27] [Article Influence: 5.1] [Reference Citation Analysis]
63 Sumida Y, Yoneda M, Hyogo H, Yamaguchi K, Ono M, Fujii H, Eguchi Y, Suzuki Y, Imai S, Kanemasa K, Fujita K, Chayama K, Yasui K, Saibara T, Kawada N, Fujimoto K, Kohgo Y, Okanoue T; Japan Study Group of Nonalcoholic Fatty Liver Disease (JSG-NAFLD). A simple clinical scoring system using ferritin, fasting insulin, and type IV collagen 7S for predicting steatohepatitis in nonalcoholic fatty liver disease. J Gastroenterol. 2011;46:257-268. [PMID: 20842510 DOI: 10.1007/s00535-010-0305-6] [Cited by in Crossref: 131] [Cited by in F6Publishing: 116] [Article Influence: 10.9] [Reference Citation Analysis]
64 Grandison GA, Angulo P. Can NASH be diagnosed, graded, and staged noninvasively? Clin Liver Dis. 2012;16:567-585. [PMID: 22824481 DOI: 10.1016/j.cld.2012.05.001] [Cited by in Crossref: 44] [Cited by in F6Publishing: 44] [Article Influence: 4.4] [Reference Citation Analysis]
65 Kojima H, Sakurai S, Matsumura M, Umemoto N, Uemura M, Morimoto H, Tamagawa Y, Fukui H. Cryptogenic cirrhosis in the region where obesity is not prevalent. World J Gastroenterol 2006; 12(13): 2080-2085 [PMID: 16610061 DOI: 10.3748/wjg.v12.i13.2080] [Cited by in CrossRef: 23] [Cited by in F6Publishing: 22] [Article Influence: 1.4] [Reference Citation Analysis]
66 Nobili V, Alisi A, Vania A, Tiribelli C, Pietrobattista A, Bedogni G. The pediatric NAFLD fibrosis index: a predictor of liver fibrosis in children with non-alcoholic fatty liver disease. BMC Med. 2009;7:21. [PMID: 19409076 DOI: 10.1186/1741-7015-7-21] [Cited by in Crossref: 82] [Cited by in F6Publishing: 80] [Article Influence: 6.3] [Reference Citation Analysis]
67 Gao Y, Song LX, Jiang MN, Ge GY, Jia YJ. Effects of traditional chinese medicine on endotoxin and its receptors in rats with non-alcoholic steatohepatitis. Inflammation. 2008;31:121-132. [PMID: 18302012 DOI: 10.1007/s10753-008-9057-3] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 1.4] [Reference Citation Analysis]
68 Cobbina E, Akhlaghi F. Non-alcoholic fatty liver disease (NAFLD) - pathogenesis, classification, and effect on drug metabolizing enzymes and transporters. Drug Metab Rev. 2017;49:197-211. [PMID: 28303724 DOI: 10.1080/03602532.2017.1293683] [Cited by in Crossref: 137] [Cited by in F6Publishing: 130] [Article Influence: 27.4] [Reference Citation Analysis]
69 Brunt EM. Pathology of nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol. 2010;7:195-203. [PMID: 20195271 DOI: 10.1038/nrgastro.2010.21] [Cited by in Crossref: 318] [Cited by in F6Publishing: 297] [Article Influence: 26.5] [Reference Citation Analysis]
70 Iacobellis A, Marcellini M, Andriulli A, Perri F, Leandro G, Devito R, Nobili V. Non invasive evaluation of liver fibrosis in paediatric patients with nonalcoholic steatohepatitis. World J Gastroenterol 2006; 12(48): 7821-7825 [PMID: 17203527 DOI: 10.3748/wjg.v12.i48.7821] [Cited by in CrossRef: 33] [Cited by in F6Publishing: 32] [Article Influence: 2.1] [Reference Citation Analysis]
71 Hadizadeh F, Faghihimani E, Adibi P. Nonalcoholic fatty liver disease: Diagnostic biomarkers. World J Gastrointest Pathophysiol 2017; 8(2): 11-26 [PMID: 28573064 DOI: 10.4291/wjgp.v8.i2.11] [Cited by in CrossRef: 47] [Cited by in F6Publishing: 37] [Article Influence: 9.4] [Reference Citation Analysis]
72 Maleki I, Aminafshari MR, Taghvaei T, Hosseini V, Rafiei A, Torabizadeh Z, Barzin M, Orang E. Serum immunoglobulin A concentration is a reliable biomarker for liver fibrosis in non-alcoholic fatty liver disease. World J Gastroenterol 2014; 20(35): 12566-12573 [PMID: 25253959 DOI: 10.3748/wjg.v20.i35.12566] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
73 Ratziu V, Massard J, Charlotte F, Messous D, Imbert-Bismut F, Bonyhay L, Tahiri M, Munteanu M, Thabut D, Cadranel JF, Le Bail B, de Ledinghen V, Poynard T;  LIDO Study Group;  CYTOL study group. Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease. BMC Gastroenterol. 2006;6:6. [PMID: 16503961 DOI: 10.1186/1471-230x-6-6] [Cited by in Crossref: 290] [Cited by in F6Publishing: 110] [Article Influence: 18.1] [Reference Citation Analysis]
74 Povero D, Panera N, Eguchi A, Johnson CD, Papouchado BG, de Araujo Horcel L, Pinatel EM, Alisi A, Nobili V, Feldstein AE. Lipid-induced hepatocyte-derived extracellular vesicles regulate hepatic stellate cell via microRNAs targeting PPAR-γ. Cell Mol Gastroenterol Hepatol 2015;1:646-663.e4. [PMID: 26783552 DOI: 10.1016/j.jcmgh.2015.07.007] [Cited by in Crossref: 82] [Cited by in F6Publishing: 87] [Article Influence: 11.7] [Reference Citation Analysis]
75 Rosa H, Parise ER. Is there a place for serum laminin determination in patients with liver disease and cancer? World J Gastroenterol 2008; 14(23): 3628-3632 [PMID: 18595129 DOI: 10.3748/wjg.14.3628] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 14] [Article Influence: 0.9] [Reference Citation Analysis]
76 Mirza MS. Obesity, Visceral Fat, and NAFLD: Querying the Role of Adipokines in the Progression of Nonalcoholic Fatty Liver Disease. ISRN Gastroenterol. 2011;2011:592404. [PMID: 21991518 DOI: 10.5402/2011/592404] [Cited by in Crossref: 63] [Cited by in F6Publishing: 72] [Article Influence: 5.7] [Reference Citation Analysis]
77 Ban CR, Twigg SM. Fibrosis in diabetes complications: pathogenic mechanisms and circulating and urinary markers. Vasc Health Risk Manag. 2008;4:575-596. [PMID: 18827908 DOI: 10.2147/vhrm.s1991] [Cited by in Crossref: 131] [Cited by in F6Publishing: 90] [Article Influence: 9.4] [Reference Citation Analysis]
78 Lefere S, Van de Velde F, Devisscher L, Bekaert M, Raevens S, Verhelst X, Van Nieuwenhove Y, Praet M, Hoorens A, Van Steenkiste C, Van Vlierberghe H, Lapauw B, Geerts A. Serum vascular cell adhesion molecule-1 predicts significant liver fibrosis in non-alcoholic fatty liver disease. Int J Obes (Lond) 2017;41:1207-13. [PMID: 28461687 DOI: 10.1038/ijo.2017.102] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 5.0] [Reference Citation Analysis]
79 Kessoku T, Ogawa Y, Yoneda M, Imajo K, Sumida Y, Eguchi Y, Fujii H, Hyogo H, Ono M, Suzuki Y, Kawaguchi T, Chayama K, Tanaka S, Fujimoto K, Anzai K, Saibara T, Sata M, Itoh Y, Nakajima A, (JSG-NAFLD) TOJSGON. Simple scoring system for predicting cirrhosis in nonalcoholic fatty liver disease. World J Gastroenterol 2014; 20(29): 10108-10114 [PMID: 25110437 DOI: 10.3748/wjg.v20.i29.10108] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
80 Cheah MC, McCullough AJ, Goh GB. Current Modalities of Fibrosis Assessment in Non-alcoholic Fatty Liver Disease. J Clin Transl Hepatol. 2017;5:261-271. [PMID: 28936407 DOI: 10.14218/jcth.2017.00009] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 2.6] [Reference Citation Analysis]
81 Almpanis Z, Demonakou M, Tiniakos D. Evaluation of liver fibrosis: "Something old, something new…". Ann Gastroenterol 2016;29:445-53. [PMID: 27708509 DOI: 10.20524/aog.2016.0046] [Cited by in Crossref: 8] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
82 Alkhouri N, Feldstein AE. Noninvasive diagnosis of nonalcoholic fatty liver disease: Are we there yet? Metabolism. 2016;65:1087-1095. [PMID: 26972222 DOI: 10.1016/j.metabol.2016.01.013] [Cited by in Crossref: 40] [Cited by in F6Publishing: 35] [Article Influence: 6.7] [Reference Citation Analysis]
83 Caussy C. Should We Screen High-Risk Populations for NAFLD? Curr Hepatology Rep 2019;18:433-43. [DOI: 10.1007/s11901-019-00497-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
84 Takamura M, Kanefuji T, Suda T, Yokoo T, Kamimura H, Tsuchiya A, Kamimura K, Tamura Y, Igarashi M, Kawai H, Yamagiwa S, Nomoto M, Aoyagi Y. Value of shear wave velocity measurements for the risk assessment of hepatocellular carcinoma development in patients with nonalcoholic fatty liver disease : HCC risk assessment by VTTQ. Hepatol Int 2014;8:240-9. [PMID: 26202505 DOI: 10.1007/s12072-014-9517-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
85 Brunt EM, Tiniakos DG. Histopathology of nonalcoholic fatty liver disease. World J Gastroenterol 2010; 16(42): 5286-5296 [PMID: 21072891 DOI: 10.3748/wjg.v16.i42.5286] [Cited by in CrossRef: 230] [Cited by in F6Publishing: 210] [Article Influence: 19.2] [Reference Citation Analysis]
86 Monsour HP Jr, Frenette CT, Wyne K. Fatty liver: a link to cardiovascular disease--its natural history, pathogenesis, and treatment. Methodist Debakey Cardiovasc J 2012;8:21-5. [PMID: 23227282 DOI: 10.14797/mdcj-8-3-21] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
87 Jeong S, Kim K, Chang J, Choi S, Kim SM, Son JS, Lee G, Kim W, Park SM. Development of a simple nonalcoholic fatty liver disease scoring system indicative of metabolic risks and insulin resistance. Ann Transl Med 2020;8:1414. [PMID: 33313159 DOI: 10.21037/atm-20-2951] [Reference Citation Analysis]
88 Basaranoglu M, Basaranoglu G, Sabuncu T, Sentürk H. Fructose as a key player in the development of fatty liver disease. World J Gastroenterol 2013; 19(8): 1166-1172 [PMID: 23482247 DOI: 10.3748/wjg.v19.i8.1166] [Cited by in CrossRef: 135] [Cited by in F6Publishing: 118] [Article Influence: 15.0] [Reference Citation Analysis]
89 Bhathena J, Kulamarva A, Martoni C, Urbanska AM, Malhotra M, Paul A, Prakash S. Diet-induced metabolic hamster model of nonalcoholic fatty liver disease. Diabetes Metab Syndr Obes 2011;4:195-203. [PMID: 21760736 DOI: 10.2147/DMSO.S18435] [Cited by in Crossref: 4] [Cited by in F6Publishing: 12] [Article Influence: 0.4] [Reference Citation Analysis]
90 Guan W, Cheng F, Wu H, Cao Q, Zhu X, Fan Y, Zhu H, Zhou Y. GATA binding protein 3 is correlated with leptin regulation of PPARγ1 in hepatic stellate cells. J Cell Mol Med 2017;21:568-78. [PMID: 27709831 DOI: 10.1111/jcmm.13002] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
91 Culafic M, Vezmar Kovacevic S, Dopsaj V, Stulic M, Vlaisavljevic Z, Miljkovic B, Culafic D. A Simple Index for Nonalcoholic Steatohepatitis-HUFA-Based on Routinely Performed Blood Tests. Medicina (Kaunas). 2019;55. [PMID: 31163711 DOI: 10.3390/medicina55060243] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
92 Marra F, Lotersztajn S. Pathophysiology of NASH: perspectives for a targeted treatment. Curr Pharm Des. 2013;19:5250-5269. [PMID: 23394092 DOI: 10.2174/1381612811399990344] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
93 Bethanis SK, Theocharis SE. Leptin in the field of hepatic fibrosis: a pivotal or an incidental player? Dig Dis Sci. 2006;51:1685-1696. [PMID: 16958000 DOI: 10.1007/s10620-006-9126-0] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 0.9] [Reference Citation Analysis]
94 Yamada S, Kimura M, Saito Y, Saito H. Nrf2-mediated anti-oxidant effects contribute to suppression of non-alcoholic steatohepatitis-associated hepatocellular carcinoma in murine model. J Clin Biochem Nutr 2018;63:123-8. [PMID: 30279623 DOI: 10.3164/jcbn.17-125] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
95 Hegazy M, Saleh SA, Ezzat A, Behiry ME. Novel Application of the Traditional Lipid Ratios as Strong Risk Predictors of NASH. Diabetes Metab Syndr Obes 2020;13:297-305. [PMID: 32104026 DOI: 10.2147/DMSO.S229590] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
96 Ghoshal UC, Baba CS, Ghoshal U, Alexander G, Misra A, Saraswat VA, Choudhuri G. Low-grade small intestinal bacterial overgrowth is common in patients with non-alcoholic steatohepatitis on quantitative jejunal aspirate culture. Indian J Gastroenterol. 2017;36:390-399. [PMID: 29034439 DOI: 10.1007/s12664-017-0797-6] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 4.4] [Reference Citation Analysis]
97 Jin YJ, Shim JH, Kim GA, Yu E, Kim KM, Lim YS, Lee HC. Clinicobiochemical prediction of biopsy-proven cases of severe hepatic fibrosis in patients with chronic hepatitis C infection. BMJ Open 2014;4:e006255. [PMID: 25431223 DOI: 10.1136/bmjopen-2014-006255] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
98 Anstee QM, Targher G, Day CP. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nat Rev Gastroenterol Hepatol. 2013;10:330-344. [PMID: 23507799 DOI: 10.1038/nrgastro.2013.41] [Cited by in Crossref: 861] [Cited by in F6Publishing: 806] [Article Influence: 95.7] [Reference Citation Analysis]
99 Sakugawa H, Nakayoshi T, Kobashigawa K, Yamashiro T, Maeshiro T, Miyagi S, Shiroma J, Toyama A, Nakayoshi T, Kinjo F, Saito A. Clinical usefulness of biochemical markers of liver fibrosis in patients with nonalcoholic fatty liver disease. World J Gastroenterol 2005; 11(2): 255-259 [PMID: 15633226 DOI: 10.3748/wjg.v11.i2.255] [Cited by in CrossRef: 102] [Cited by in F6Publishing: 104] [Article Influence: 6.0] [Reference Citation Analysis]
100 Berzigotti A, Garcia-Tsao G, Bosch J, Grace ND, Burroughs AK, Morillas R, Escorsell A, Garcia-Pagan JC, Patch D, Matloff DS, Groszmann RJ;  Portal Hypertension Collaborative Group. Obesity is an independent risk factor for clinical decompensation in patients with cirrhosis. Hepatology. 2011;54:555-561. [PMID: 21567436 DOI: 10.1002/hep.24418] [Cited by in Crossref: 155] [Cited by in F6Publishing: 135] [Article Influence: 14.1] [Reference Citation Analysis]
101 Kleiner DE, Makhlouf HR. Histology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis in Adults and Children. Clin Liver Dis 2016;20:293-312. [PMID: 27063270 DOI: 10.1016/j.cld.2015.10.011] [Cited by in Crossref: 111] [Cited by in F6Publishing: 90] [Article Influence: 15.9] [Reference Citation Analysis]
102 Hsu CC, Ness E, Kowdley KV. Nutritional Approaches to Achieve Weight Loss in Nonalcoholic Fatty Liver Disease. Adv Nutr. 2017;8:253-265. [PMID: 28298270 DOI: 10.3945/an.116.013730] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 4.0] [Reference Citation Analysis]
103 Anstee QM, Goldin RD. Mouse models in non-alcoholic fatty liver disease and steatohepatitis research. Int J Exp Pathol. 2006;87:1-16. [PMID: 16436109 DOI: 10.1111/j.0959-9673.2006.00465.x] [Cited by in Crossref: 487] [Cited by in F6Publishing: 482] [Article Influence: 30.4] [Reference Citation Analysis]
104 Chan AW, Patel YA, Choi S. Aging of the Liver: What This Means for Patients with HIV. Curr HIV/AIDS Rep 2016;13:309-17. [PMID: 27557619 DOI: 10.1007/s11904-016-0332-x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
105 Asselah T, Rubbia-Brandt L, Marcellin P, Negro F. Steatosis in chronic hepatitis C: why does it really matter? Gut. 2006;55:123-130. [PMID: 16344578 DOI: 10.1136/gut.2005.069757] [Cited by in Crossref: 257] [Cited by in F6Publishing: 241] [Article Influence: 16.1] [Reference Citation Analysis]
106 Soresi M, Cabibi D, Giglio RV, Martorana S, Guercio G, Porcasi R, Terranova A, Lazzaro LA, Emma MR, Augello G, Cervello M, Pantuso G, Montalto G, Giannitrapani L. The Prevalence of NAFLD and Fibrosis in Bariatric Surgery Patients and the Reliability of Noninvasive Diagnostic Methods.Biomed Res Int. 2020;2020:5023157. [PMID: 32420347 DOI: 10.1155/2020/5023157] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
107 Marra F, Lotersztajn S. Pathophysiology of NASH: perspectives for a targeted treatment. Curr Pharm Des 2013;19:5250-69. [PMID: 23394092 DOI: 10.2174/13816128113199990344] [Cited by in Crossref: 94] [Cited by in F6Publishing: 96] [Article Influence: 11.8] [Reference Citation Analysis]
108 Rahimlou M, Ahmadnia H, Hekmatdoost A. Dietary supplements and pediatric non-alcoholic fatty liver disease: Present and the future. World J Hepatol 2015; 7(25): 2597-2602 [PMID: 26557952 DOI: 10.4254/wjh.v7.i25.2597] [Cited by in Crossref: 33] [Cited by in F6Publishing: 33] [Article Influence: 4.7] [Reference Citation Analysis]
109 Arulanandan A, Loomba R. Non-invasive Testing for NASH and NASH with Advanced Fibrosis: Are We There Yet? Curr Hepatol Rep 2015;14:109-18. [PMID: 26500833 DOI: 10.1007/s11901-015-0263-9] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
110 Rath MM, Panigrahi MK, Pattnaik K, Bhuyan P, Kar SK, Misra B, Misra D, Meher C, Agrawal O, Rath J, Singh SP. Histological Evaluation of Non-alcoholic Fatty Liver Disease and Its Correlation with Different Noninvasive Scoring Systems with Special Reference to Fibrosis: A Single Center Experience. J Clin Exp Hepatol 2016;6:291-6. [PMID: 28003718 DOI: 10.1016/j.jceh.2016.08.006] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
111 Sharma KS, Lim P, Brotherston TM, Smith P. The Prophylactic Use of Lipid Emulsion Therapy in the Excision of Invasive Malignant Melanoma under Local Anaesthetic in a Morbidly Obese Patient. Case Rep Surg 2013;2013:765279. [PMID: 23401838 DOI: 10.1155/2013/765279] [Reference Citation Analysis]
112 Cauchy F, Fuks D, Zarzavadjian Le Bian A, Belghiti J, Costi R. Metabolic syndrome and non-alcoholic fatty liver disease in liver surgery: The new scourges? World J Hepatol 2014; 6(5): 306-314 [PMID: 24868324 DOI: 10.4254/wjh.v6.i5.306] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
113 Harrison SA, Di Bisceglie AM. Advances in the Understanding and Treatment of Nonalcoholic Fatty Liver Disease: . Drugs 2003;63:2379-94. [DOI: 10.2165/00003495-200363220-00001] [Cited by in Crossref: 41] [Cited by in F6Publishing: 35] [Article Influence: 2.2] [Reference Citation Analysis]
114 Lee HW, Park SY, Kim SU, Jang JY, Park H, Kim JK, Lee CK, Chon YE, Han KH. Discrimination of Nonalcoholic Steatohepatitis Using Transient Elastography in Patients with Nonalcoholic Fatty Liver Disease. PLoS One. 2016;11:e0157358. [PMID: 27284700 DOI: 10.1371/journal.pone.0157358] [Cited by in Crossref: 38] [Cited by in F6Publishing: 38] [Article Influence: 6.3] [Reference Citation Analysis]
115 Dai K, Qi JY, Tian DY. Leptin administration exacerbates thioacetamide-induced liver fibrosis in mice. World J Gastroenterol 2005; 11(31): 4822-4826 [PMID: 16097051 DOI: 10.3748/wjg.v11.i31.4822] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 16] [Article Influence: 0.8] [Reference Citation Analysis]
116 Kamada Y, Ono M, Hyogo H, Fujii H, Sumida Y, Yamada M, Mori K, Tanaka S, Maekawa T, Ebisutani Y, Yamamoto A, Takamatsu S, Yoneda M, Kawada N, Chayama K, Saibara T, Takehara T, Miyoshi E; Japan Study Group of Nonalcoholic Fatty Liver Disease (JSG‐NAFLD). Use of Mac-2 binding protein as a biomarker for nonalcoholic fatty liver disease diagnosis. Hepatol Commun 2017;1:780-91. [PMID: 29404494 DOI: 10.1002/hep4.1080] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 4.6] [Reference Citation Analysis]
117 Zhai X, Yan K, Fan J, Niu M, Zhou Q, Zhou Y, Chen H, Zhou Y. The β-catenin pathway contributes to the effects of leptin on SREBP-1c expression in rat hepatic stellate cells and liver fibrosis. Br J Pharmacol 2013;169:197-212. [PMID: 23347184 DOI: 10.1111/bph.12114] [Cited by in Crossref: 44] [Cited by in F6Publishing: 44] [Article Influence: 5.5] [Reference Citation Analysis]
118 Iacobellis G, Moschetta A, Ribaudo MC, Zappaterreno A, Iannucci CV, Leonetti F. Normal serum alanine aminotransferase activity in uncomplicated obesity. World J Gastroenterol 2005; 11(38): 6018-6021 [PMID: 16273617 DOI: 10.3748/wjg.v11.i38.6018] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
119 Singhvi A, Sadowsky HS, Cohen A, Demzik A, VanWagner L, Rinella M, Levitsky J. Resting and Exercise Energy Metabolism After Liver Transplantation for Nonalcoholic Steatohepatitis. Transplant Direct 2017;3:e188. [PMID: 28795140 DOI: 10.1097/TXD.0000000000000701] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.4] [Reference Citation Analysis]
120 Fernández-varo G. Marcadores serológicos de fibrosis. Gastroenterología y Hepatología 2012;35:10-6. [DOI: 10.1016/s0210-5705(12)70044-4] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
121 Kamada Y, Miyoshi E. Mac-2 Binding Protein is a Useful Liver Fibrosis Biomarker for NAFLD/NASH. Trends in Glycoscience and Glycotechnology 2017;29:E85-92. [DOI: 10.4052/tigg.1714.1e] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
122 Segura-Azuara NLÁ, Varela-Chinchilla CD, Trinidad-Calderón PA. MAFLD/NAFLD Biopsy-Free Scoring Systems for Hepatic Steatosis, NASH, and Fibrosis Diagnosis. Front Med (Lausanne) 2021;8:774079. [PMID: 35096868 DOI: 10.3389/fmed.2021.774079] [Reference Citation Analysis]
123 Madan K, Batra Y, Gupta SD, Chander B, Rajan KDA, Tewatia MS, Panda SK, Acharya SK. Non-alcoholic fatty liver disease may not be a severe disease at presentation among Asian Indians. World J Gastroenterol 2006; 12(21): 3400-3405 [PMID: 16733858 DOI: 10.3748/wjg.v12.i21.3400] [Cited by in CrossRef: 43] [Cited by in F6Publishing: 43] [Article Influence: 2.7] [Reference Citation Analysis]
124 Caballería L, Torán P. Detección precoz de la enfermedad hepática crónica en población adulta aparentemente sana en atención primaria. Gastroenterología y Hepatología 2012;35:23-9. [DOI: 10.1016/s0210-5705(12)70046-8] [Reference Citation Analysis]
125 Yamada S, Takashina Y, Watanabe M, Nagamine R, Saito Y, Kamada N, Saito H. Bile acid metabolism regulated by the gut microbiota promotes non-alcoholic steatohepatitis-associated hepatocellular carcinoma in mice. Oncotarget 2018;9:9925-39. [PMID: 29515780 DOI: 10.18632/oncotarget.24066] [Cited by in Crossref: 49] [Cited by in F6Publishing: 48] [Article Influence: 12.3] [Reference Citation Analysis]
126 Pattnaik K, Bhuyan P, Singh A, Singh SP, Nath P, Kar S, Misra B, Rath J. Biopsy Proven Fibrosis in Non-Alcoholic Fatty Liver Disease: An Analysis of Risk Factors. J Clin Exp Hepatol 2018;8:367-74. [PMID: 30563997 DOI: 10.1016/j.jceh.2017.12.008] [Reference Citation Analysis]
127 Bruno S, Maisonneuve P, Castellana P, Rotmensz N, Rossi S, Maggioni M, Persico M, Colombo A, Monasterolo F, Casadei-Giunchi D. Incidence and risk factors for non-alcoholic steatohepatitis: prospective study of 5408 women enrolled in Italian tamoxifen chemoprevention trial. BMJ. 2005;330:932. [PMID: 15746106 DOI: 10.1136/bmj.38391.663287.e0] [Cited by in Crossref: 142] [Cited by in F6Publishing: 43] [Article Influence: 8.4] [Reference Citation Analysis]
128 Tanikawa K, Torimura T. Studies on oxidative stress in liver diseases: important future trends in liver research. Med Mol Morphol 2006;39:22-7. [PMID: 16575511 DOI: 10.1007/s00795-006-0313-z] [Cited by in Crossref: 50] [Cited by in F6Publishing: 48] [Article Influence: 3.1] [Reference Citation Analysis]
129 Di Mauro S, Scamporrino A, Filippello A, Di Pino A, Scicali R, Malaguarnera R, Purrello F, Piro S. Clinical and Molecular Biomarkers for Diagnosis and Staging of NAFLD. Int J Mol Sci 2021;22:11905. [PMID: 34769333 DOI: 10.3390/ijms222111905] [Reference Citation Analysis]
130 Mazza A, Fruci B, Garinis GA, Giuliano S, Malaguarnera R, Belfiore A. The role of metformin in the management of NAFLD. Exp Diabetes Res. 2012;2012:716404. [PMID: 22194737 DOI: 10.1155/2012/716404] [Cited by in Crossref: 98] [Cited by in F6Publishing: 100] [Article Influence: 8.9] [Reference Citation Analysis]
131 Kathirvel E, Morgan K, Nandgiri G, Sandoval BC, Caudill MA, Bottiglieri T, French SW, Morgan TR. Betaine improves nonalcoholic fatty liver and associated hepatic insulin resistance: a potential mechanism for hepatoprotection by betaine. Am J Physiol Gastrointest Liver Physiol. 2010;299:G1068-G1077. [PMID: 20724529 DOI: 10.1152/ajpgi.00249.2010] [Cited by in Crossref: 89] [Cited by in F6Publishing: 84] [Article Influence: 7.4] [Reference Citation Analysis]
132 Calzadilla Bertot L, Adams LA. The Natural Course of Non-Alcoholic Fatty Liver Disease. Int J Mol Sci. 2016;17. [PMID: 27213358 DOI: 10.3390/ijms17050774] [Cited by in Crossref: 248] [Cited by in F6Publishing: 242] [Article Influence: 41.3] [Reference Citation Analysis]
133 Cho HC. Prevalence and Factors Associated with Nonalcoholic Fatty Liver Disease in a Nonobese Korean Population. Gut Liver. 2016;10:117-125. [PMID: 26260755 DOI: 10.5009/gnl14444] [Cited by in Crossref: 34] [Cited by in F6Publishing: 35] [Article Influence: 5.7] [Reference Citation Analysis]
134 Yoneda M, Mawatari H, Fujita K, Yonemitsu K, Kato S, Takahashi H, Kirikoshi H, Inamori M, Nozaki Y, Abe Y, Kubota K, Saito S, Iwasaki T, Terauchi Y, Togo S, Maeyama S, Nakajima A. Type IV collagen 7s domain is an independent clinical marker of the severity of fibrosis in patients with nonalcoholic steatohepatitis before the cirrhotic stage. J Gastroenterol. 2007;42:375-381. [PMID: 17530362 DOI: 10.1007/s00535-007-2014-3] [Cited by in Crossref: 61] [Cited by in F6Publishing: 56] [Article Influence: 4.1] [Reference Citation Analysis]
135 Clark JM, Diehl AM. Hepatic steatosis and type 2 diabetes mellitus. Curr Diab Rep. 2002;2:210-215. [PMID: 12643175 DOI: 10.1007/s11892-002-0085-3] [Cited by in Crossref: 74] [Cited by in F6Publishing: 75] [Article Influence: 3.9] [Reference Citation Analysis]
136 Smith BW, Adams LA. Nonalcoholic fatty liver disease and diabetes mellitus: pathogenesis and treatment. Nat Rev Endocrinol. 2011;7:456-465. [PMID: 21556019 DOI: 10.1038/nrendo.2011.72] [Cited by in Crossref: 200] [Cited by in F6Publishing: 190] [Article Influence: 18.2] [Reference Citation Analysis]
137 Bolukbas FF, Bolukbas C, Zeyrek F, Aslan M, Bahcecioglu HI, Ozardali I. High rate of seropositivity of Chlamydia pneumoniae IgA in male patients with nonalcoholic steatohepatitis. Dig Dis Sci 2005;50:1141-5. [PMID: 15986871 DOI: 10.1007/s10620-005-2721-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
138 Yoneda M, Mawatari H, Fujita K, Yonemitsu K, Kato S, Takahashi H, Kirikoshi H, Inamori M, Nozaki Y, Abe Y. Type IV collagen 7s domain is an independent clinical marker of the severity of fibrosis in patients with nonalcoholic steatohepatitis before the cirrhotic stage. J Gastroenterol. 2007;42:375-381. [PMID: 17530362 DOI: 10.1007/s00535-2014-3] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
139 Tobari M, Hashimoto E. Characteristic Features of Nonalcoholic Fatty Liver Disease in Japan with a Focus on the Roles of Age, Sex and Body Mass Index. Gut Liver 2020;14:537-45. [PMID: 31887811 DOI: 10.5009/gnl19236] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 13.0] [Reference Citation Analysis]
140 Lee TH, Han SH, Yang JD, Kim D, Ahmed M. Prediction of Advanced Fibrosis in Nonalcoholic Fatty Liver Disease: An Enhanced Model of BARD Score. Gut Liver 2013;7:323-8. [PMID: 23710314 DOI: 10.5009/gnl.2013.7.3.323] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 2.2] [Reference Citation Analysis]
141 Kruschitz R, Luger M, Kienbacher C, Trauner M, Klammer C, Schindler K, Langer FB, Prager G, Krebs M, Ludvik B. The Effect of Roux-en-Y vs. Omega-Loop Gastric Bypass on Liver, Metabolic Parameters, and Weight Loss. Obes Surg 2016;26:2204-12. [PMID: 27003699 DOI: 10.1007/s11695-016-2083-6] [Cited by in Crossref: 31] [Cited by in F6Publishing: 25] [Article Influence: 6.2] [Reference Citation Analysis]
142 Magnuson AM, Regan DP, Booth AD, Fouts JK, Solt CM, Hill JL, Dow SW, Foster MT. High-fat diet induced central adiposity (visceral fat) is associated with increased fibrosis and decreased immune cellularity of the mesenteric lymph node in mice. Eur J Nutr 2020;59:1641-54. [PMID: 31165249 DOI: 10.1007/s00394-019-02019-z] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
143 Durazzo M, Belci P, Collo A, Prandi V, Pistone E, Martorana M, Gambino R, Bo S. Gender specific medicine in liver diseases: A point of view. World J Gastroenterol 2014; 20(9): 2127-2135 [PMID: 24605011 DOI: 10.3748/wjg.v20.i9.2127] [Cited by in CrossRef: 27] [Cited by in F6Publishing: 22] [Article Influence: 3.4] [Reference Citation Analysis]
144 Ciupińska-Kajor M, Hartleb M, Kajor M, Kukla M, Wyleżoł M, Lange D, Liszka L. Hepatic angiogenesis and fibrosis are common features in morbidly obese patients. Hepatol Int 2013;7:233-40. [PMID: 23519653 DOI: 10.1007/s12072-011-9320-9] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 1.3] [Reference Citation Analysis]
145 McGettigan BM, McMahan RH, Luo Y, Wang XX, Orlicky DJ, Porsche C, Levi M, Rosen HR. Sevelamer Improves Steatohepatitis, Inhibits Liver and Intestinal Farnesoid X Receptor (FXR), and Reverses Innate Immune Dysregulation in a Mouse Model of Non-alcoholic Fatty Liver Disease. J Biol Chem 2016;291:23058-67. [PMID: 27605663 DOI: 10.1074/jbc.M116.731042] [Cited by in Crossref: 22] [Cited by in F6Publishing: 12] [Article Influence: 3.7] [Reference Citation Analysis]
146 Qureshi K, Clements RH, Abrams GA. The Utility of the “NAFLD Fibrosis Score” in Morbidly Obese Subjects with NAFLD. OBES SURG 2008;18:264-70. [DOI: 10.1007/s11695-007-9295-8] [Cited by in Crossref: 41] [Cited by in F6Publishing: 38] [Article Influence: 2.9] [Reference Citation Analysis]
147 Dunn W, Xu R, Wingard DL, Rogers C, Angulo P, Younossi ZM, Schwimmer JB. Suspected nonalcoholic fatty liver disease and mortality risk in a population-based cohort study. Am J Gastroenterol. 2008;103:2263-2271. [PMID: 18684196 DOI: 10.1111/j.1572-0241.2008.02034.x] [Cited by in Crossref: 213] [Cited by in F6Publishing: 205] [Article Influence: 15.2] [Reference Citation Analysis]
148 de Avelar CR, Pereira EM, de Farias Costa PR, de Jesus RP, de Oliveira LPM. Effect of silymarin on biochemical indicators in patients with liver disease: Systematic review with meta-analysis. World J Gastroenterol 2017; 23(27): 5004-5017 [PMID: 28785154 DOI: 10.3748/wjg.v23.i27.5004] [Cited by in CrossRef: 34] [Cited by in F6Publishing: 25] [Article Influence: 6.8] [Reference Citation Analysis]
149 Castera L, Friedrich-Rust M, Loomba R. Noninvasive Assessment of Liver Disease in Patients With Nonalcoholic Fatty Liver Disease. Gastroenterology. 2019;156:1264-1281.e4. [PMID: 30660725 DOI: 10.1053/j.gastro.2018.12.036] [Cited by in Crossref: 310] [Cited by in F6Publishing: 296] [Article Influence: 103.3] [Reference Citation Analysis]
150 Dam-Larsen S, Franzmann M, Andersen IB, Christoffersen P, Jensen LB, Sørensen TI, Becker U, Bendtsen F. Long term prognosis of fatty liver: risk of chronic liver disease and death. Gut. 2004;53:750-755. [PMID: 15082596 DOI: 10.1136/gut.2003.019984] [Cited by in Crossref: 345] [Cited by in F6Publishing: 312] [Article Influence: 19.2] [Reference Citation Analysis]
151 Albano E, Mottaran E, Vidali M, Reale E, Saksena S, Occhino G, Burt AD, Day CP. Immune response towards lipid peroxidation products as a predictor of progression of non-alcoholic fatty liver disease to advanced fibrosis. Gut. 2005;54:987-993. [PMID: 15951547 DOI: 10.1136/gut.2004.057968] [Cited by in Crossref: 135] [Cited by in F6Publishing: 133] [Article Influence: 7.9] [Reference Citation Analysis]
152 Rahimlou M, Yari Z, Hekmatdoost A, Alavian SM, Keshavarz SA. Ginger Supplementation in Nonalcoholic Fatty Liver Disease: A Randomized, Double-Blind, Placebo-Controlled Pilot Study. Hepat Mon. 2016;16:e34897. [PMID: 27110262 DOI: 10.5812/hepatmon.34897] [Cited by in Crossref: 41] [Cited by in F6Publishing: 37] [Article Influence: 6.8] [Reference Citation Analysis]
153 Kwon YD, Ko KO, Lim JW, Cheon EJ, Song YH, Yoon JM. Usefulness of Transient Elastography for Non-Invasive Diagnosis of Liver Fibrosis in Pediatric Non-Alcoholic Steatohepatitis. J Korean Med Sci 2019;34:e165. [PMID: 31197983 DOI: 10.3346/jkms.2019.34.e165] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
154 Singh S, Allen AM, Wang Z, Prokop LJ, Murad MH, Loomba R. Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies. Clin Gastroenterol Hepatol 2015; 13: 643-54. quiz e39-40. [PMID: 24768810 DOI: 10.1016/j.cgh.2014.04.014] [Cited by in Crossref: 683] [Cited by in F6Publishing: 646] [Article Influence: 85.4] [Reference Citation Analysis]
155 Mahmoud AM, Ding X, Dutta D, Singh VP, Kim K. Detecting hepatic steatosis using ultrasound-induced thermal strain imaging: an ex vivo animal study. Phys Med Biol 2014;59:881-95. [PMID: 24487698 DOI: 10.1088/0031-9155/59/4/881] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 1.9] [Reference Citation Analysis]
156 Fitzpatrick E, Dhawan A. Noninvasive biomarkers in non-alcoholic fatty liver disease: Current status and a glimpse of the future. World J Gastroenterol 2014; 20(31): 10851-10863 [PMID: 25152587 DOI: 10.3748/wjg.v20.i31.10851] [Cited by in CrossRef: 68] [Cited by in F6Publishing: 59] [Article Influence: 8.5] [Reference Citation Analysis]
157 Gan L, Chitturi S, Farrell GC. Mechanisms and implications of age-related changes in the liver: nonalcoholic Fatty liver disease in the elderly. Curr Gerontol Geriatr Res. 2011;2011:831536. [PMID: 21918648 DOI: 10.1155/2011/831536] [Cited by in Crossref: 46] [Cited by in F6Publishing: 52] [Article Influence: 4.2] [Reference Citation Analysis]
158 de Meijer VE, Le HD, Meisel JA, Akhavan Sharif MR, Pan A, Nosé V, Puder M. Dietary fat intake promotes the development of hepatic steatosis independently from excess caloric consumption in a murine model. Metabolism. 2010;59:1092-1105. [PMID: 20060143 DOI: 10.1016/j.metabol.2009.11.006] [Cited by in Crossref: 67] [Cited by in F6Publishing: 66] [Article Influence: 5.6] [Reference Citation Analysis]
159 Hsu WF, Sheen LY, Lin HJ, Chang HH. A Review of Western and Traditional Chinese Medical Approaches to Managing Nonalcoholic Fatty Liver Disease. Evid Based Complement Alternat Med 2016;2016:6491420. [PMID: 27872651 DOI: 10.1155/2016/6491420] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
160 Zarzavadjian Le Bian A, Costi R, Constantinides V, Smadja C. Metabolic Disorders, Non-Alcoholic Fatty Liver Disease and Major Liver Resection: An Underestimated Perioperative Risk. J Gastrointest Surg 2012;16:2247-55. [DOI: 10.1007/s11605-012-2044-x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 1.8] [Reference Citation Analysis]
161 Losekann A, Weston AC, de Mattos AA, Tovo CV, de Carli LA, Espindola MB, Pioner SR, Coral GP. Non-Alcoholic Steatohepatitis (NASH): Risk Factors in Morbidly Obese Patients. Int J Mol Sci. 2015;16:25552-25559. [PMID: 26512661 DOI: 10.3390/ijms161025552] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 3.1] [Reference Citation Analysis]
162 Goh GB, Pagadala MR, Dasarathy J, Unalp-Arida A, Pai RK, Yerian L, Khiyami A, Sourianarayanane A, Sargent R, Hawkins C, Dasarathy S, McCullough AJ. Age impacts ability of aspartate-alanine aminotransferase ratio to predict advanced fibrosis in nonalcoholic Fatty liver disease. Dig Dis Sci. 2015;60:1825-1831. [PMID: 25708897 DOI: 10.1007/s10620-015-3529-8] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
163 Pearce SG, Thosani NC, Pan JJ. Noninvasive biomarkers for the diagnosis of steatohepatitis and advanced fibrosis in NAFLD. Biomark Res. 2013;1:7. [PMID: 24252302 DOI: 10.1186/2050-7771-1-7] [Cited by in Crossref: 52] [Cited by in F6Publishing: 47] [Article Influence: 5.8] [Reference Citation Analysis]
164 Geier A, Tiniakos D, Denk H, Trauner M. From the origin of NASH to the future of metabolic fatty liver disease. Gut 2021:gutjnl-2020-323202. [PMID: 33632710 DOI: 10.1136/gutjnl-2020-323202] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
165 Nah EH, Cho S, Park H, Noh D, Kwon E, Cho HI. Subclinical steatohepatitis and advanced liver fibrosis in health examinees with nonalcoholic fatty liver disease (NAFLD) in 10 South Korean cities: A retrospective cross-sectional study. PLoS One 2021;16:e0260477. [PMID: 34818372 DOI: 10.1371/journal.pone.0260477] [Reference Citation Analysis]
166 Emamat H, Noori M, Foroughi F, Rismanchi M, Eini-Zinab H, Hekmatdoost A. An Accessible and Pragmatic Experimental Model of Nonalcoholic Fatty Liver Disease. Middle East J Dig Dis. 2016;8:109-115. [PMID: 27252817 DOI: 10.15171/mejdd.2016.15] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
167 Filozof C, Goldstein BJ, Williams RN, Sanyal A. Non-Alcoholic Steatohepatitis: Limited Available Treatment Options but Promising Drugs in Development and Recent Progress Towards a Regulatory Approval Pathway. Drugs 2015;75:1373-92. [PMID: 26201461 DOI: 10.1007/s40265-015-0437-3] [Cited by in Crossref: 47] [Cited by in F6Publishing: 39] [Article Influence: 7.8] [Reference Citation Analysis]
168 Dennis BB, Sallam S, Perumpail BJ, Shah ND, Kim D, Cholankeril G, Ahmed A. Management of Cardiometabolic Complications in Patients With Nonalcoholic Fatty Liver Disease: A Review of the Literature With Recommendations. J Clin Gastroenterol 2021;55:747-56. [PMID: 34469404 DOI: 10.1097/MCG.0000000000001555] [Reference Citation Analysis]
169 Basaranoglu M, Turhan N, Sonsuz A, Basaranoglu G. Mallory-Denk Bodies in chronic hepatitis. World J Gastroenterol 2011; 17(17): 2172-2177 [PMID: 21633525 DOI: 10.3748/wjg.v17.i17.2172] [Cited by in CrossRef: 22] [Cited by in F6Publishing: 19] [Article Influence: 2.0] [Reference Citation Analysis]
170 Baran B, Akyüz F. Non-alcoholic fatty liver disease: What has changed in the treatment since the beginning? World J Gastroenterol 2014; 20(39): 14219-14229 [PMID: 25339808 DOI: 10.3748/wjg.v20.i39.14219] [Cited by in CrossRef: 25] [Cited by in F6Publishing: 25] [Article Influence: 3.1] [Reference Citation Analysis]
171 Syn WK, Bruckner-Holt C, Farmer A, Howdle S, Bateman J. Liver biopsy in a district general hospital: Changes over two decades. World J Gastroenterol 2007; 13(40): 5336-5342 [PMID: 17879403 DOI: 10.3748/wjg.v13.i40.5336] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
172 Papachristodoulou A, Kavvadas D, Karamitsos A, Papamitsou T, Chatzidimitriou M, Sioga A. Diagnosis and Staging of Pediatric Non-Alcoholic Fatty Liver Disease: Is Classical Ultrasound the Answer? Pediatr Rep 2021;13:312-21. [PMID: 34201230 DOI: 10.3390/pediatric13020039] [Reference Citation Analysis]
173 Asselah T, Boyer N, Guimont MC, Cazals-Hatem D, Tubach F, Nahon K, Daïkha H, Vidaud D, Martinot M, Vidaud M, Degott C, Valla D, Marcellin P. Liver fibrosis is not associated with steatosis but with necroinflammation in French patients with chronic hepatitis C. Gut 2003;52:1638-43. [PMID: 14570735 DOI: 10.1136/gut.52.11.1638] [Cited by in Crossref: 80] [Cited by in F6Publishing: 85] [Article Influence: 4.4] [Reference Citation Analysis]
174 Das SK, Balakrishnan V. Role of cytokines in the pathogenesis of non-alcoholic Fatty liver disease. Indian J Clin Biochem. 2011;26:202-209. [PMID: 22468051 DOI: 10.1007/s12291-011-0121-7] [Cited by in Crossref: 52] [Cited by in F6Publishing: 52] [Article Influence: 4.7] [Reference Citation Analysis]
175 de Bruyn G, Graviss EA. A systematic review of the diagnostic accuracy of physical examination for the detection of cirrhosis. BMC Med Inform Decis Mak 2001;1:6. [PMID: 11806763 DOI: 10.1186/1472-6947-1-6] [Cited by in Crossref: 19] [Cited by in F6Publishing: 13] [Article Influence: 0.9] [Reference Citation Analysis]
176 Heinemann F, Birk G, Stierstorfer B. Deep learning enables pathologist-like scoring of NASH models. Sci Rep 2019;9:18454. [PMID: 31804575 DOI: 10.1038/s41598-019-54904-6] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
177 Romano M, Vacante M, Cristaldi E, Colonna V, Gargante MP, Cammalleri L, Malaguarnera M. L-carnitine treatment reduces steatosis in patients with chronic hepatitis C treated with alpha-interferon and ribavirin. Dig Dis Sci. 2008;53:1114-1121. [PMID: 17939042 DOI: 10.1007/s10620-007-9983-1] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 1.6] [Reference Citation Analysis]
178 Novakovic T, Mekic M, Smilic L, Smilic T, Inić-Kostic B, Jovicevic L, Mirkovic Z, Milinic S. Anthropometric and biochemical characteristics of patients with nonalcoholic fatty liver diagnosed by non-invasive diagnostic methods. Med Arh. 2014;68:22-26. [PMID: 24783906 DOI: 10.5455/medarh.2014.68.22-26] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
179 Sert A, Pirgon O, Aypar E, Yılmaz H, Dündar B. Relationship between aspartate aminotransferase-to-platelet ratio index and carotid intima-media thickness in obese adolescents with non-alcoholic fatty liver disease. J Clin Res Pediatr Endocrinol 2013;5:182-8. [PMID: 24072087 DOI: 10.4274/Jcrpe.891] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
180 Han MA, Saouaf R, Ayoub W, Todo T, Mena E, Noureddin M. Magnetic resonance imaging and transient elastography in the management of Nonalcoholic Fatty Liver Disease (NAFLD). Expert Rev Clin Pharmacol. 2017;10:379-390. [PMID: 28277807 DOI: 10.1080/17512433.2017.1299573] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 3.2] [Reference Citation Analysis]
181 Honma Y, Sumida K, Ogino N, Kusanaga M, Minami S, Kumei S, Matsuoka H, Watanabe T, Hiura M, Abe S, Shibata M, Harada M. A Young Adult Patient with Nonalcoholic Steatohepatitis Developed Severe Gastroesophageal Varices Associated with Severe Obesity and Diabetes Mellitus. Case Rep Gastroenterol 2018;12:487-96. [PMID: 30283282 DOI: 10.1159/000492423] [Reference Citation Analysis]
182 Cheng Z, Lv Y, Pang S, Bai R, Wang M, Lin S, Xu T, Spalding D, Habib N, Xu R. Kallistatin, a new and reliable biomarker for the diagnosis of liver cirrhosis. Acta Pharm Sin B 2015;5:194-200. [PMID: 26579446 DOI: 10.1016/j.apsb.2015.02.003] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 2.4] [Reference Citation Analysis]
183 Bechtold M, Palmer J, Valtos J, Iasiello C, Sowers J. Metabolic syndrome in the elderly. Curr Diab Rep 2006;6:64-71. [PMID: 16522283 DOI: 10.1007/s11892-006-0054-3] [Cited by in Crossref: 33] [Cited by in F6Publishing: 24] [Article Influence: 2.1] [Reference Citation Analysis]
184 Enomoto H, Aizawa N, Nishikawa H, Ikeda N, Sakai Y, Takata R, Hasegawa K, Nakano C, Nishimura T, Yoh K, Ishii A, Takashima T, Iwata Y, Iijima H, Nishiguchi S. Relationship Between Hepatic Steatosis and the Elevation of Aminotransferases in HBV-Infected Patients With HBe-Antigen Negativity and a Low Viral Load. Medicine (Baltimore) 2016;95:e3565. [PMID: 27124068 DOI: 10.1097/MD.0000000000003565] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
185 Day CP. Non-alcoholic steatohepatitis (NASH): where are we now and where are we going? Gut. 2002;50:585-588. [PMID: 11950797 DOI: 10.1136/gut.50.5.585] [Cited by in Crossref: 123] [Cited by in F6Publishing: 116] [Article Influence: 6.2] [Reference Citation Analysis]
186 Godoy-Matos AF, Silva Júnior WS, Valerio CM. NAFLD as a continuum: from obesity to metabolic syndrome and diabetes.Diabetol Metab Syndr. 2020;12:60. [PMID: 32684985 DOI: 10.1186/s13098-020-00570-y] [Cited by in Crossref: 35] [Cited by in F6Publishing: 35] [Article Influence: 17.5] [Reference Citation Analysis]
187 Zafrani ES. Non-alcoholic fatty liver disease: an emerging pathological spectrum. Virchows Arch. 2004;444:3-12. [PMID: 14685853 DOI: 10.1007/s00428-003-0943-7] [Cited by in Crossref: 71] [Cited by in F6Publishing: 58] [Article Influence: 3.7] [Reference Citation Analysis]
188 Blais P, Husain N, Kramer JR, Kowalkowski M, El-Serag H, Kanwal F. Nonalcoholic fatty liver disease is underrecognized in the primary care setting. Am J Gastroenterol 2015;110:10-4. [PMID: 24890441 DOI: 10.1038/ajg.2014.134] [Cited by in Crossref: 69] [Cited by in F6Publishing: 64] [Article Influence: 8.6] [Reference Citation Analysis]
189 Guha IN, Parkes J, Roderick PR, Harris S, Rosenberg WM. Non-invasive markers associated with liver fibrosis in non-alcoholic fatty liver disease. Gut 2006;55:1650-60. [PMID: 17047111 DOI: 10.1136/gut.2006.091454] [Cited by in Crossref: 89] [Cited by in F6Publishing: 85] [Article Influence: 5.6] [Reference Citation Analysis]
190 Park KS, Lee YS, Park HW, Seo SH, Jang BG, Hwang JY, Cho KB, Hwang JS, Ahn SH, Kang YN, Kim GC. Factors associated or related to with pathological severity of nonalcoholic fatty liver disease. Korean J Intern Med 2004;19:19-26. [PMID: 15053039 DOI: 10.3904/kjim.2004.19.1.19] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 1.1] [Reference Citation Analysis]
191 Uslusoy HS, Nak SG, Gülten M, Bıyıklı Z. Liver histology according to the presence of metabolic syndrome in nonalcoholic fatty liver disease cases. World J Gastroenterol 2009; 15(9): 1093-1098 [PMID: 19266602 DOI: 10.3748/wjg.15.1093] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 8] [Article Influence: 0.3] [Reference Citation Analysis]
192 Gordon SC, Kachru N, Parker E, Korrer S, Ozbay AB, Wong RJ. Health Care Use and Costs Among Patients With Nonalcoholic Steatohepatitis With Advanced Fibrosis Using the Fibrosis-4 Score. Hepatol Commun 2020;4:998-1011. [PMID: 32626832 DOI: 10.1002/hep4.1524] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
193 Dunn W, Xu R, Schwimmer JB. Modest wine drinking and decreased prevalence of suspected nonalcoholic fatty liver disease. Hepatology 2008;47:1947-54. [PMID: 18454505 DOI: 10.1002/hep.22292] [Cited by in Crossref: 163] [Cited by in F6Publishing: 146] [Article Influence: 11.6] [Reference Citation Analysis]
194 Dunn W, Xu R, Wingard DL, Rogers C, Angulo P, Younossi ZM, Schwimmer JB. Suspected nonalcoholic fatty liver disease and mortality risk in a population-based cohort study. Am J Gastroenterol. 2008;103:2263-2271. [PMID: 18684196 DOI: 10.1111/j.1572-0241.2008.02034] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
195 Kennedy C, Redden D, Gray S, Eckhoff D, Massoud O, McGuire B, Alkurdi B, Bloomer J, DuBay DA. Equivalent survival following liver transplantation in patients with non-alcoholic steatohepatitis compared with patients with other liver diseases. HPB (Oxford). 2012;14:625-634. [PMID: 22882200 DOI: 10.1111/j.1477-2574.2012.00497.x] [Cited by in Crossref: 38] [Cited by in F6Publishing: 35] [Article Influence: 3.8] [Reference Citation Analysis]
196 Rocha R, Cotrim HP, Carvalho FM, Siqueira AC, Braga H, Freitas LA. Body mass index and waist circumference in non-alcoholic fatty liver disease. J Hum Nutr Diet 2005;18:365-70. [PMID: 16150132 DOI: 10.1111/j.1365-277X.2005.00634.x] [Cited by in Crossref: 59] [Cited by in F6Publishing: 30] [Article Influence: 3.5] [Reference Citation Analysis]
197 Singh DK, Sakhuja P, Malhotra V, Gondal R, Sarin SK. Independent Predictors of Steatohepatitis and Fibrosis in Asian Indian Patients with Non-Alcoholic Steatohepatitis. Dig Dis Sci 2008;53:1967-76. [DOI: 10.1007/s10620-007-0074-0] [Cited by in Crossref: 35] [Cited by in F6Publishing: 34] [Article Influence: 2.3] [Reference Citation Analysis]
198 Mitsuka Y, Midorikawa Y, Abe H, Matsumoto N, Moriyama M, Haradome H, Sugitani M, Tsuji S, Takayama T. A prediction model for the grade of liver fibrosis using magnetic resonance elastography. BMC Gastroenterol 2017;17:133. [PMID: 29179678 DOI: 10.1186/s12876-017-0700-z] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
199 Shukla A, Kapileswar S, Gogtay N, Joshi A, Dhore P, Shah C, Abraham P, Bhatia S. Simple biochemical parameters and a novel score correlate with absence of fibrosis in patients with nonalcoholic fatty liver disease. Indian J Gastroenterol 2015;34:281-5. [DOI: 10.1007/s12664-015-0580-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
200 Rinella ME, Sanyal AJ. Management of NAFLD: a stage-based approach. Nat Rev Gastroenterol Hepatol. 2016;13:196-205. [PMID: 26907882 DOI: 10.1038/nrgastro.2016.3] [Cited by in Crossref: 150] [Cited by in F6Publishing: 144] [Article Influence: 25.0] [Reference Citation Analysis]
201 Nasr P, Ignatova S, Kechagias S, Ekstedt M. Natural history of nonalcoholic fatty liver disease: A prospective follow-up study with serial biopsies. Hepatol Commun. 2018;2:199-210. [PMID: 29404527 DOI: 10.1002/hep4.1134] [Cited by in Crossref: 48] [Cited by in F6Publishing: 47] [Article Influence: 9.6] [Reference Citation Analysis]
202 Shah AG, Lydecker A, Murray K, Tetri BN, Contos MJ, Sanyal AJ;  Nash Clinical Research Network. Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2009;7:1104-1112. [PMID: 19523535 DOI: 10.1016/j.cgh.2009.05.033] [Cited by in Crossref: 620] [Cited by in F6Publishing: 561] [Article Influence: 47.7] [Reference Citation Analysis]
203 Eguchi Y, Eguchi T, Mizuta T, Ide Y, Yasutake T, Iwakiri R, Hisatomi A, Ozaki I, Yamamoto K, Kitajima Y, Kawaguchi Y, Kuroki S, Ono N. Visceral fat accumulation and insulin resistance are important factors in nonalcoholic fatty liver disease. J Gastroenterol. 2006;41:462-469. [PMID: 16799888 DOI: 10.1007/s00535-006-1790-5] [Cited by in Crossref: 189] [Cited by in F6Publishing: 174] [Article Influence: 11.8] [Reference Citation Analysis]
204 Yoneda M, Uchiyama T, Kato S, Endo H, Fujita K, Yoneda K, Mawatari H, Iida H, Takahashi H, Kirikoshi H, Inamori M, Nozaki Y, Kobayashi N, Kubota K, Saito S, Maeyama S, Sagara M, Aburatani H, Kodama T, Nakajima A. Plasma Pentraxin3 is a novel marker for nonalcoholic steatohepatitis (NASH). BMC Gastroenterol 2008;8:53. [PMID: 19014569 DOI: 10.1186/1471-230X-8-53] [Cited by in Crossref: 54] [Cited by in F6Publishing: 28] [Article Influence: 3.9] [Reference Citation Analysis]
205 Sporea I, Şirli R, Başa E, Cornianu M, Popescu A, Dănilă M, Focşa M. The value of transabdominal ultrasound for assessment of the severity of liver steatosis as compared to liver biopsy. Open Medicine 2009;4:490-5. [DOI: 10.2478/s11536-009-0067-9] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
206 Marion AW, Baker AJ, Dhawan A. Fatty liver disease in children. Arch Dis Child 2004;89:648-52. [PMID: 15210498 DOI: 10.1136/adc.2003.029942] [Cited by in Crossref: 53] [Cited by in F6Publishing: 47] [Article Influence: 2.9] [Reference Citation Analysis]
207 Deleve LD, Wang X, Guo Y. Sinusoidal endothelial cells prevent rat stellate cell activation and promote reversion to quiescence. Hepatology 2008;48:920-30. [PMID: 18613151 DOI: 10.1002/hep.22351] [Cited by in Crossref: 207] [Cited by in F6Publishing: 192] [Article Influence: 14.8] [Reference Citation Analysis]
208 Machado MV, Cortez-Pinto H. Non-alcoholic fatty liver disease: What the clinician needs to know. World J Gastroenterol 2014; 20(36): 12956-12980 [PMID: 25278691 DOI: 10.3748/wjg.v20.i36.12956] [Cited by in CrossRef: 109] [Cited by in F6Publishing: 91] [Article Influence: 13.6] [Reference Citation Analysis]
209 Kupčová V, Fedelešová M, Bulas J, Kozmonová P, Turecký L. Overview of the Pathogenesis, Genetic, and Non-Invasive Clinical, Biochemical, and Scoring Methods in the Assessment of NAFLD. Int J Environ Res Public Health 2019;16:E3570. [PMID: 31554274 DOI: 10.3390/ijerph16193570] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]